Julian Baker Baker Bros. Advisors
Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITMN
INTERMUNE INC
ITMN
|
+$93M |
| 2 |
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
|
+$34.7M |
| 3 |
ACOR
Acorda Therapeutics
ACOR
|
+$33.7M |
| 4 |
Heron Therapeutics
HRTX
|
+$29M |
| 5 |
XNPT
XENOPORT, INC.
XNPT
|
+$18.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arrowhead Research
ARWR
|
+$41.4M |
| 2 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$35.9M |
| 3 |
MDVN
MEDIVATION, INC.
MDVN
|
+$25.4M |
| 4 |
Halozyme
HALO
|
+$8.89M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
+$8.88M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 48.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ZGNX
51
DELISTED
Zogenix, Inc.
ZGNX
| $6.69M | 0.09% |
293,800
-50,075
| -15% | -$1.63M |
|
|
ACGN
52
DELISTED
Aceragen Inc
ACGN
| $6.58M | 0.08% |
11,873
-11,472
| -49% | -$7.85M |
|
53
Xencor
XNCR
$2.07B
| $6.36M | 0.08% |
542,363
-7,637
| -1% | -$80.2K |
|
|
AERI
54
DELISTED
Aerie Pharmaceuticals
AERI
| $6.34M | 0.08% |
299,356
-644
| -0.2% | -$13K |
|
55
Novavax
NVAX
$1.47B
| $5.54M | 0.07% |
61,168
-3,178
| -5% | -$355K |
|
56
Ironwood Pharmaceuticals
IRWD
$709M
| $5.5M | 0.07% |
532,715
-119,400
| -18% | -$1.34M |
|
|
TBRA
57
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
| $5.01M | 0.06% |
+44,444
| New | +$3.12M |
|
58
Ligand Pharmaceuticals
LGND
$5.71B
| $4.94M | 0.06% |
117,660
| – | – |
|
59
Ultragenyx Pharmaceutical
RARE
$2.55B
| $4.89M | 0.06% |
+100,000
| New | +$5.15M |
|
|
EPZM
60
DELISTED
Epizyme, Inc
EPZM
| $4.87M | 0.06% |
214,012
-5,988
| -3% | -$182K |
|
|
OSIR
61
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
| $4.75M | 0.06% |
361,530
-13,752
| -4% | -$215K |
|
|
RXDX
62
DELISTED
Ignyta, Inc.
RXDX
| $4.74M | 0.06% |
+571,000
| New | +$5.35M |
|
|
PTLA
63
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $4.73M | 0.06% |
182,591
-41,843
| -19% | -$1.12M |
|
|
CYTR
64
DELISTED
CytRx Corp
CYTR
| $4.71M | 0.06% |
+225,000
| New | +$7.98M |
|
|
BLUE
65
DELISTED
bluebird bio
BLUE
| $4.51M | 0.06% |
15,306
+6,470
| +73% | +$1.96M |
|
|
AKTX
66
Akari Therapeutics
AKTX
$15.3M
| $4.37M | 0.06% |
+84
| New | +$4.75M |
|
67
Travere Therapeutics
TVTX
$6.19B
| $4.19M | 0.05% |
+197,178
| New | +$3.03M |
|
68
Ionis Pharmaceuticals
IONS
$9.93B
| $4.16M | 0.05% |
96,303
-150,733
| -61% | -$7.31M |
|
|
BDSI
69
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $3.55M | 0.05% |
421,005
-425,000
| -50% | -$3.43M |
|
|
FURX
70
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
| $3.51M | 0.04% |
+40,309
| New | +$3.11M |
|
71
Enanta Pharmaceuticals
ENTA
$392M
| $3.24M | 0.04% |
80,957
-28,140
| -26% | -$1.02M |
|
72
MacroGenics
MGNX
$261M
| $2.68M | 0.03% |
96,165
-3,835
| -4% | -$135K |
|
|
LJPC
73
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $2.39M | 0.03% |
+221,631
| New | +$2.17M |
|
74
Madrigal Pharmaceuticals
MDGL
$11.9B
| $2.15M | 0.03% |
14,286
| – | – |
|
75
Savara
SVRA
$1.15B
| $2.04M | 0.03% |
+42,857
| New | +$2.35M |
|
Similar funds
Julian Baker's Q1 2014 Portfolio in Review
As of Q1 2014, Julian Baker held 114 positions worth $7.87B, up 11% from $7.1B the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Julian Baker withdrew a net $1.35B in Q1 2014, closing 6 positions and reducing 44 holdings. Its most notable exit was MEDIVATION, INC., an estimated $25.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 48% of assets, down from 50% a quarter earlier.
Against the trend, Julian Baker opened a new position in Acorda Therapeutics worth $37.9M.
- Julian Baker's largest Q1 2014 buy was Acorda Therapeutics: 8,333 shares worth $37.9M.
- Julian Baker added most to INTERMUNE INC in Q1 2014, an estimated $93M increase.
- Julian Baker's biggest Q1 2014 reduction was Arrowhead Research, cutting an estimated $41.4M.
- Julian Baker fully exited MEDIVATION, INC. in Q1 2014, selling an estimated $25.4M.
- Julian Baker's ten largest holdings make up 73% of its $7.87B portfolio in Q1 2014.
- Julian Baker opened 19 new positions and closed 6 in Q1 2014.
- Julian Baker's portfolio value rose 11% quarter-over-quarter to $7.87B.
Based on Baker Bros. Advisors's 13F filing for Q1 2014, filed 15 May 2014.